IMPACT: Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer by Annika Herlemann et al Full article: europeanurology.com/article/S0302-… Annika Herlemann #UroSoMe #PCa

SOLAR Phase 2 trial: multimodal therapy without long-term castration ➡️de novo oligometastatic PCa ➡️RP or RT to the primary + MDT (SBRT) + Intensified systemic therapy for 6 months (ADT+Apa+Abi) ➡️Primary endpoint: percentage of patients with testosterone ≥150 and undetectable

Don't miss the latest Urology Cheay Sheet!

A nomogram for predicting renal insufficiency in #UTUC after radical nephroureterectomy. #ExpertCommentary Dr. Bishoy M. Faltas WCM Englander Institute for Precision Medicine discusses work by Patrick Hensley, MD et al. in European Urology Oncology showing strong accuracy in predicting renal function post-RNU > bit.ly/3XOzChg

💫🌟🔬 ProBio: Innovation in mCRPC 🔬🌟💫 nature Advanced Prostate Cancer Consensus Conference OncoAlert 1️⃣ARPIs extend the time without clinical benefit compared to taxanes and physician’s choice (11.1 vs. 6.9 and 7.4 months). ⏳ 2️⃣ Greater overall survival with ARPIs (38.7 months) vs. taxanes and

Have you previewed the #EMUC24 Scientific Programme? Take a look to see what important genito-urinary cancer topics will be addressed by leading experts this year in Lisbon. #UrologicalCancers ESTRO ESMO - Eur. Oncology Check out the full programme here 👇 scientific-programme.uroweb.org/EMUC24/program…

Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following ProstatectomyA Nonrandomized Controlled Trial jamanetwork.com/journals/jamao… This phase 2, single-arm trial evaluated the efficacy of olaparib, a poly(ADP-ribose) polymerase

Thank you BJU International for highlighting our work! The #BladderCancer space is rapidly evolving and we hope this work sheds some light on treatment strategies for patients with NMIBC and who might be a candidate for bladder sparing therapy UT Southwestern Urology

Karim Fizazi putting into perspective the PEACE 3 trial at #ESMO24 presidential symposium ESMO - Eur. Oncology Neeraj Agarwal, MD, FASCO OncoAlert

PSMA-PET and PROMISE re-define stage and risk in pts with PCa UroToday.com #ESMO24 ✏️n=2,414; 901 (37.3%) deaths ✏️Quantitative PSMA-PET by PROMISE nomogram, superior to: - STARCAP at initial staging (AUC 0.73 vs. 0.54; p = 0.02) - EAU risk score at BCR (AUC 0.69 vs. 0.52; p

AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or observation for 1 year. The pembrolizumab group had a median disease-free survival twice as long as the observation group. nej.md/4gh1b9D #ESMO24

Decipher Decipher by Veracyte proving to be a strong signature in Adv prostate cancer #ESMO24 Great work exploring a range of signatures on the #STAMPEDE trial AttardLab Nick James Elai Davicioni Looking forward to the publication! #ESMOAmbassadors

Perioperative studies at MIBC are starting to come out. Today, NIAGARA (first of them) demonstrates statistically significant increase in PFS and OS but... really all patients need the one year of adjuvant lO?

STAMPEDE: Decipher score predictive of OS treatment benefit with docetaxel addition to ADT in both low & high volume pts 📌2nd predictive biomarker in PCa space, following ArteraAI for ST-ADT intensification in int risk pts receiving XRT UroToday.com #ESMO24

AMBASSADOR: Fase III Ca Urotelial músculo invasor post-cistectomía pembrolizumab 1 vs observar ESMO - Eur. Oncology en NEJM Andrea Apolo, M.D. Petros Grivas ✅ Beneficio sobrevida libre de enfermedad DFS 💢 Independiente de PD-L1 y status ganglionar 📛 Recurrencias metastásicas fq brazo control

Original Article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma (AMBASSADOR) nej.md/4gh1b9D #ESMO24 | ESMO - Eur. Oncology

Promising biomarkers in mHSPC -- niven mehra #ESMO24 UroToday.com

The honesty, thoughtfulness, and wit of Christopher Sweeney, MBBS Phase 3 trials of Immunotherapy in Prostate Cancer -- A Case Study of "Failed All-Comer Strategy" ⚡️8 negative trials 💰 >$700 million USD 👨‍🦰 7,305 patients #ESMO24 UroToday.com

JCOG1019: Non-inferiority ph 3 RCT of WW vs BCG in primary T1 NMIBC pts w/ T0 on repeat TUR (n=263) 🔹Primary endpoint: No difference in T1 RFS (HR: 0.69 favoring WW; p for non-inf: 0.001) ⬆️Worse any-stage RFS in WW arm (HR: 1.33) 🔹No difference in OS or MFS 📌WW reasonable

SunRISe-4: Interim analysis of neoadjuvant TAR-200 (intravesical) + cetrelimab (n=51) or cetrelimab alone (n=31) in MIBC RC pts 🔹pCR: 42% (TAR-200+cet); 23% (cet) 🔹≤ypT1N0 (pOR): 60% & 36% ⬆️pCR & pOR in cT2 pts for TAR-200+cet: 48% & 68% ⬆️pCR as # TAR-200 doses ⬆️ (1-2=27%,